VTGN - Vistagen social anxiety nasal spray meets phase 3 primary endpoint
2023-08-07 09:35:31 ET
- Vistagen ( NASDAQ: VTGN ) said that a phase 3 study of fasedienol, a nasal spray to treat social anxiety disorder, met its primary and secondary endpoints.
- The candidate, which has a novel mechanism of action, led to statistically significant improvement in Subjective Units of Distress Scale (SUDS) score compared to placebo in a public speaking challenge.
- In addition, the drug achieved a statistically significant difference in the number of clinician-assessed responders between fasedienol and placebo as measured by the clinical global impression-improvement (CGI-I) scale, the secondary endpoint.
- Describing fasedienol's novel mechanism of action, Vistagen said that it "regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system, without systemic distribution, potentiation of GABA-A receptors or direct activity on neurons in the brain."
- Seeking Alpha's Quant Rating has viewed Vistagen ( VTGN ) as a strong sell since May 18.
For further details see:
Vistagen social anxiety nasal spray meets phase 3 primary endpoint